Sumatriptan
Selective Serotonin (5ht1) Agonists
Sold as SUVEXX · IMITREX · TOSYMRA · IMIGRAN SUBJECT
- Drug class
- Selective Serotonin (5ht1) Agonists
- Availability
- Prescription only
- Routes
- Oral, Subcutaneous, Nasal
- Markets covered
- 3
- Products on record
- 198
- FDA reports (12 mo)
- 2,123
Overview
Plain-language summary, compiled from the cited regulatory records
Sumatriptan is a medication belonging to the drug class of selective serotonin (5HT1) agonists [1]. It is approved for the acute treatment of migraine headaches, with or without aura, in adults [1]. Additionally, it is indicated for the acute treatment of cluster headaches in adults [1].
It is important to use Sumatriptan only when a clear diagnosis of migraine or cluster headache has been established [1]. If a patient does not respond to the first migraine attack treated with Sumatriptan, the diagnosis should be reconsidered before administering it for subsequent attacks [1]. Sumatriptan is available under various brand names, including TOSYMRA [1].
In the past 12 months, there have been 2123 adverse event reports associated with Sumatriptan [2]. The most frequently reported reactions include drug ineffectiveness, headache, off-label use, nausea, and fatigue [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 146 | May 22, 2026 |
| CA Canada | Health Canada | 43 | May 21, 2026 |
| US United States | FDA | 9 | April 15, 2026 |
GBUnited Kingdom· MHRA
146 products
Uses
Sumatriptan is indicated for the acute treatment of migraine attacks with or without aura.
How to take
CACanada· Health Canada
43 products
Uses
JAMP
Sumatriptan / Naproxen Sodium (sumatriptan and naproxen sodium tablets) is indicated for the acute treatment of migraine attacks with or without aura in adults. JAMP Sumatriptan / Naproxen Sodium is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, basilar, or ophthalmoplegic migraine (see CONTRAINDICATIONS).
Safety and efficacy of sumatriptan and naproxen sodium has not been established for cluster headache, which is present in an older, predominantly male population. JAMP Sumatriptan / Naproxen Sodium should only be used if a clear diagnosis of migraine headache has been established.
1 Pediatrics Pediatrics <18 years: The safety and efficacy of sumatriptan and naproxen sodium tablets in pediatric patients have not been established. JAMP Sumatriptan / Naproxen Sodium is not indicated for use in pediatric patients.
USUnited States· FDA
9 products
Uses
1 INDICATIONS AND USAGE Sumatriptan injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use Use only if a clear diagnosis of migraine or cluster headache has been established.
If a patient has no response to the first migraine or cluster headache attack treated with sumatriptan injection, reconsider the diagnosis before sumatriptan injection is administered to treat any subsequent attacks. Sumatriptan injection is not indicated for the prevention of migraine or cluster headache attacks.
Sumatriptan injection is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for: Acute treatment of migraine with or without aura in adults. (1) Acute treatment of cluster headache in adults. (1) Limitations of Use Use only if a clear diagnosis of migraine or cluster headache has been established.
(1) Not indicated for the prophylactic therapy of migraine or cluster headache attacks. (1)
Drug interactions
Known interactions involving Sumatriptan. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 281. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL163630595 · revised May 22, 2026
- [2]Health Canada (DPD) · 02566974 · revised April 16, 2026
- [3]FDA DailyMed · 1909558d-8342-4a… · revised April 15, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.